Recent guidelines for non-alcoholic fatty liver disease (NAFLD): Are they already outdated and in need of supplementation?

Non-alcoholic fatty liver disease (NAFLD), a highly prevalent disease and unmet clinical need, has been commonly associated with metabolic comorbidities, including obesity, type 2 diabetes (T2D), hypertension, and hyperlipidemia. Since no FDA approved treatments exist to date, recent guidelines recommend lifestyle interventions, bariatric surgery, and pharmacotherapy, i.e., glucagon-like peptide-1 receptor agonists (GLP-1RA), peroxisome proliferator-activated receptor- γ (PPAR-γ) agonists, and SGLT-2 inhibitors for its treatment.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research